From L-R: Bitterroot Bio CEO Pavan Cheruvu, and co-founders Irv Weissman and Nick Leeper

June 7, 2023 09:53 AM EDT

Bitterroot Bio nabs $145M Series A with a plan to tackle challenging cancer target for heart medicines

Lei Lei Wu

News Reporter

The founders of cancer biotech Forty Seven had initially envisioned that the company would also work on developing heart drugs that cut down inflammation. Before …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bitterroot Bio nabs $145M Series A with a plan to tackle challenging cancer target for heart medicines

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Bit­ter­root Bio nabs $145M Se­ries A with a plan to tack­le chal­leng­ing can­cer tar­get for heart med­i­cines

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Bitterroot Bio nabs $145M Series A with a plan to tackle challenging cancer target for heart medicines